Malignant Prostate Neoplasm

Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz… (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

Analysing 101 samples of metastatic prostate cancer biopsy, a high friequency of structural variants in the AR gene were identified (23/101), comprising a heterogeneous mix of deletion, inversion, tra… (full text at CIViC)

PMID 31932493 · Li et al., 2020 · Open in CIViC

In a clinical study including 168 patients treated with abiraterone or enzalutamide, a multivariate analysis including tumor burden and TP53 status show no significant correlation between AR-V1, AR-V2… (full text at CIViC)

PMID 30209161 · De Laere et al., 2019 · Open in CIViC

Analysis was performed on 224 advanced prostate cancer (PCA) patient samples which had clinical outcome information. Elevated PSA levels in patients after radical prostatectomy are associated with me… (full text at CIViC)

PMID 19244107 · Guo et al., 2009 · Open in CIViC

Using a panel of three androgen-insensitive prostate cancer cell lines (C-81, CWR-R1 and 22Rv1), a novel AR protein isoform was identified. This protein was found to be encoded by three novel alternat… (full text at CIViC)

PMID 19244107 · Guo et al., 2009 · Open in CIViC

Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer ce… (full text at CIViC)

PMID 23779130 · Joseph et al., 2013 · Open in CIViC

In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations. Within the AR mutation cohort, 78… (full text at CIViC)

PMID 26000489 · Robinson et al., 2015 · Open in CIViC

In a clinical study including 78 patients with metastatic CRPC, multivariate analyses show that overexpression of AR-V9 is significantly correlated to primary resistance to abiraterone (p = 0.02).

PMID 28473535 · Kohli et al., 2017 · Open in CIViC

In 31enzalutamide-treated and 31 abiraterone-treated patients, detectable levels of AR-V7 was associated with resistance in these patients with castration resistant prostate cancer.

PMID 25184630 · Antonarakis et al., 2014 · Open in CIViC

In a prospective clinical study including 52 patients, expression of AR-FL or AR-V1 or AR-V3 or AR-V7 or AR-V9 are not significantly associated with PSA response change. However, in a multivariate ana… (full text at CIViC)

PMID 31180178 · Sieuwerts et al., 2019 · Open in CIViC

In a clinical study including 54 patients treated with taxane, AR-V567es expression is significantly correlated with a response change in PSA (p = 0.04) and a decrease in PFS (p = 0.02).

PMID 30301829 · Tagawa et al., 2019 · Open in CIViC

Castration Resistant Prostate Cancer (CRPC) often develops after Androgen Deprivation Therapy due to reactivation of transcription of the Androgen Receptor (AR). Transcriptional reactivation can be du… (full text at CIViC)

PMID 28473535 · Kohli et al., 2017 · Open in CIViC

LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion.

PMID 12517791 · Hara et al., 2003 · Open in CIViC

This study (PMID 32343890) by de Bono et al, is a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) w… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC)

PMID 30797618 · Marshall et al., 2019 · Open in CIViC

Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Over… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Over… (full text at CIViC)

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

In the phase 3 TALAPRO-2 trial 805 patients with castration-resistant prostate cancer were enrolled and randomized to talazoparib or placebo plus enzalutamide treatment. Patients were tested for homol… (full text at CIViC)

PMID 37285865 · Agarwal et al., 2023 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC)

PMID 30797618 · Marshall et al., 2019 · Open in CIViC

Mutation disrupts the splice donor site, allowing read-through into the intron and termination of transcription at codon 64 Located in N-terminus RING finger domain, which is highly conserved. 57 year… (full text at CIViC)

PMID 22516946 · Leongamornlert et al., 2012 · Open in CIViC

In a study of 2,019 patients with prostate cancer, 18 had germline BRCA1 mutations, 61 had germline BRCA2 mutations and 1,940 were non-carriers. Patients with BRCA1/2 mutations had a 2-fold higher in… (full text at CIViC)

PMID 23569316 · Castro et al., 2013 · Open in CIViC

1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.

PMID 26510020 · Mateo et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In the post hoc exploratory BRCA1-only subgroup (n = 13; olaparib, n = 8; control, n = 5) of the phase III randomized open-label PROfound trial (NCT02987543), olaparib monotherapy supported Sensitivit… (full text at CIViC)

PMID 37963304 · Mateo et al., 2024 · Open in CIViC

In the BRCA‑altered cohort (n = 160; BRCA1/2 alterations) of the global, randomized, open‑label phase III PROfound trial (NCT02987543) in metastatic castration‑resistant prostate cancer (mCRPC), patie… (full text at CIViC)

PMID 37963304 · Mateo et al., 2024 · Open in CIViC

In an open-label, phase 2 study, 115 male patients with castration-resistant prostate cancer and a BRCA1/2 alteration with or without measurable disease were enrolled to receive rucaparib 600 mg twice… (full text at CIViC)

PMID 32795228 · Abida et al., 2020 · Open in CIViC